CRISM Therapeutics Corporation (CRTX) — Tangible Net Worth Ratio
CRISM Therapeutics Corporation (CRTX) has a Tangible Net Worth Ratio of 92.7% as of December 2025. This metric is calculated by deducting intangible assets (GBX104.00K) from net assets (GBX1.42 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore CRISM Therapeutics Corporation net asset momentum to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
CRISM Therapeutics Corporation Tangible Net Worth Ratio (2006–2025)
This chart shows how CRISM Therapeutics Corporation's Tangible Net Worth Ratio has changed across 19 annual periods from 2006 to 2025. As of December 2025, the ratio stands at 92.7%, reflecting net assets of GBX1.42 Million with intangible assets of GBX104.00K GBX. For live market cap and overall valuation, see CRISM Therapeutics Corporation (CRTX) market capitalisation.
Annual Tangible Net Worth Ratio for CRISM Therapeutics Corporation (2006–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for CRISM Therapeutics Corporation from 2006 to 2025, covering 19 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. See CRTX financial flexibility score to measure the company's free cash flow as a share of total liabilities.
| Year | Tangible NW Ratio | Net Assets (GBX) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 92.7% | GBX1.42 Million | GBX104.00K | GBX1.80 Million | ▼ -2.3 pp |
| 2024 | 95.0% | GBX1.48 Million | GBX74.00K | GBX1.82 Million | ▼ -5.0 pp |
| 2022 | 100.0% | GBX23.13 Million | GBX0.00 | GBX23.89 Million | ▲ +0.0 pp |
| 2021 | 100.0% | GBX30.11 Million | GBX0.00 | GBX31.24 Million | ▲ +75.1 pp |
| 2020 | 24.9% | GBX31.35 Million | GBX23.54 Million | GBX32.40 Million | ▼ -75.1 pp |
| 2019 | 100.0% | GBX20.48 Million | GBX0.00 | GBX21.34 Million | ▲ +0.0 pp |
| 2018 | 100.0% | GBX23.48 Million | GBX0.00 | GBX26.24 Million | ▲ +79.4 pp |
| 2017 | 20.6% | GBX28.20 Million | GBX22.38 Million | GBX29.14 Million | ▼ -12.2 pp |
| 2016 | 32.8% | GBX25.55 Million | GBX17.17 Million | GBX29.43 Million | ▲ +8.5 pp |
| 2015 | 24.3% | GBX15.21 Million | GBX11.51 Million | GBX15.91 Million | ▼ -18.8 pp |
| 2014 | 43.1% | GBX20.72 Million | GBX11.78 Million | GBX21.12 Million | ▲ +44.6 pp |
| 2013 | -1.5% | GBX18.05 Million | GBX18.32 Million | GBX18.13 Million | ▲ +4.5 pp |
| 2012 | -6.0% | GBX16.12 Million | GBX17.08 Million | GBX16.19 Million | ▼ -42.3 pp |
| 2011 | 36.3% | GBX21.19 Million | GBX13.50 Million | GBX21.29 Million | ▲ +0.5 pp |
| 2010 | 35.7% | GBX21.29 Million | GBX13.68 Million | GBX21.40 Million | ▲ +17.6 pp |
| 2009 | 18.1% | GBX16.52 Million | GBX13.53 Million | GBX16.81 Million | ▲ +44.2 pp |
| 2008 | -26.1% | GBX10.78 Million | GBX13.60 Million | GBX11.07 Million | ▲ +65.7 pp |
| 2007 | -91.8% | GBX6.53 Million | GBX12.53 Million | GBX6.71 Million | ▼ -124.6 pp |
| 2006 | 32.8% | GBX9.33 Million | GBX6.27 Million | GBX9.35 Million | — |